2025
Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis
Geva M, Goldberg Y, Schuring H, Tan A, Long J, Hayden M. Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis. Movement Disorders 2025, 40: 928-937. PMID: 40099482, PMCID: PMC12089908, DOI: 10.1002/mds.30164.Peer-Reviewed Original ResearchConceptsMeasures of clinical outcomeTotal motor scoreOutcome measuresUnified Huntington's Disease Rating ScaleHuntington's Disease Rating ScaleYears post-baselineEnroll-HD databaseFunctional outcome measuresManagement of Huntington's diseaseNew-user designAntidopaminergic medicationsHuntington's diseaseSymptom managementEnroll-HDClinical outcomesDisease Rating ScalePost-baselineMeasure of clinical progressionUnexposed cohortComposite Unified Huntington’s Disease Rating Scale,Motor scoresClinical measuresADM useAssociated with worse clinical outcomesRating ScaleAntidopaminergic medications in Huntington's disease
Tan A, Geva M, Goldberg Y, Schuring H, Sanson B, Rosser A, Raymond L, Reilmann R, Hayden M, Anderson K. Antidopaminergic medications in Huntington's disease. Journal Of Huntington's Disease 2025, 14: 16-29. PMID: 39973394, DOI: 10.1177/18796397241304312.Peer-Reviewed Original ResearchConceptsAntidopaminergic medicationsSymbol Digit Modalities TestHuntington's diseaseComposite Unified Huntington’s Disease Rating Scale,Unified Huntington's Disease Rating ScaleExtrapyramidal symptomsWord readingHuntington's Disease Rating ScaleVMAT2 inhibitorsBehavioral impairmentsBehavioral disordersCognitive dysfunctionCognitive functionRating ScaleADM useDisease Rating ScaleHD symptomsTotal functional capacityModal testingMotor disturbancesFunctional impairmentProgressive neurodegenerative disorderMounting body of evidenceSide effectsBody of evidence
2022
The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”
Mozafar M, Kazemian S, Hoseini E, Mohammadi M, Alimoghadam R, Shafie M, Mayeli M, Initiative T. The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”. Clinical Parkinsonism & Related Disorders 2022, 8: 100177. PMID: 36590455, PMCID: PMC9798165, DOI: 10.1016/j.prdoa.2022.100177.Peer-Reviewed Original ResearchSpecific binding ratioUric acid levelsMDS-UPDRS III scoreIII scoreHealthy controlsMDS-UPDRSFollow-upGBA mutationsBaseline uric acid levelAcid levelsGlucocerebrosidase mutationsYears of follow-upH&Y stageParkinson's Progression Markers InitiativeMovement Disorder Society Unified Parkinson's Disease Rating ScaleSporadic PDBody mass indexParkinson's Disease Rating Scale IIIParkinson's diseaseBlood uric acid levelsUnified Parkinson's Disease Rating ScaleParkinson's Disease Rating ScaleDisease Rating ScaleBaseline characteristicsClinical characteristicsDigital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson’s disease: Protocol of the mixed method, cyclic ActiveAgeing study
Torrado JC, Husebo BS, Allore HG, Erdal A, Fæø SE, Reithe H, Førsund E, Tzoulis C, Patrascu M. Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson’s disease: Protocol of the mixed method, cyclic ActiveAgeing study. PLOS ONE 2022, 17: e0275747. PMID: 36240173, PMCID: PMC9565381, DOI: 10.1371/journal.pone.0275747.Peer-Reviewed Original ResearchConceptsREM Sleep Behavior Disorder Screening QuestionnaireUnified Parkinson's Disease Rating ScaleDisease Rating ScaleGeriatric Depression ScaleApathy Evaluation ScaleParkinson's diseaseOlder adultsGeriatric Anxiety InventoryParkinson's Disease Rating ScaleClinical assessment scalesMontreal Cognitive AssessmentNew outcome measureQuality of lifeGlobal public healthHealthy older adultsClinical trialsOutcome measuresDepression ScaleLifestyle changesScreening QuestionnaireWaiting listFunctional limitationsSymptom evolutionNeurological disordersAssessment Scale
2021
Effects of gamma sensory stimulation on cognitive function in Alzheimer’s disease patients
Cimenser A, Konisky A, Shukla M, Mrozak H, Cohen J, Kolin K, Martin K, Boasso A, Hempel E, Malchano Z, Hajos M. Effects of gamma sensory stimulation on cognitive function in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056695.Peer-Reviewed Original ResearchMini-Mental State ExaminationSensory stimulationCognitive functionDisease Assessment ScaleCognitive declineSensory stimulation therapyCognitive measuresCognitive abilitiesDisease Rating ScaleCognitive testsDisease patientsAlzheimer's Disease Assessment ScaleAlzheimer's disease patientsSham groupCognitive scoresNeural activityAD-related cognitive declineOnly participantsVisual stimulationAD patientsClinical trialsState ExaminationClinical Dementia Rating SumTreatment groupsAlzheimer's Disease Rating Scale
2020
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease
Omer N, Giladi N, Gurevich T, Bar‐Shira A, Gana‐Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr‐Urtreger A, Mirelman A, Thaler A. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. Movement Disorders 2020, 35: 1249-1253. PMID: 32353202, DOI: 10.1002/mds.28066.Peer-Reviewed Original ResearchConceptsGBA-PDLRRK2-PDIdiopathic Parkinson's diseaseDisease Rating ScaleParkinson's diseaseTotal Unified Parkinson's Disease Rating ScaleUnified Parkinson's Disease Rating ScaleParkinson's Disease Rating ScaleG2019S LRRK2 mutationBetter olfactionClinical symptomsPatientsGBA genePhenotypic presentationRating ScalePerformance-based measuresPhenotypic expressionDiseaseLower scoresPresentationMutationsSymptoms
2019
Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions
Mayeli M, Mirshahvalad S, Aghamollaii V, Tafakhori A, Abdolalizadeh A, Rahmani F, Initiative A. Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions. Journal Of Neuropathology & Experimental Neurology 2019, 78: 709-716. PMID: 31305887, DOI: 10.1093/jnen/nlz054.Peer-Reviewed Original ResearchNeurofilament light chainPlasma neurofilament light chainPlasma NfL levelsNfL levelsCortical hypometabolismAlzheimer's Disease Rating ScaleMild cognitive impairmentMiddle temporal gyriLevels of neurofilament light chainNeurofilament light chain levelsLight chain levelsRegional cerebral metabolic rateCSF neurofilament light chainPlasma neurofilament light chain levelsPositron emission tomographyTemporal gyriCerebral metabolic rateCSF NfL levelsBilateral parahippocampal gyriPosterior cingulate cortexDisease Rating ScaleBaseline cohortEmission tomographyRegional CMRglcCingulate cortex
2018
Demoralization in Parkinson disease
Koo BB, Chow CA, Shah DR, Khan FH, Steinberg B, Derlein D, Nalamada K, Para KS, Kakade VM, Patel AS, de Figueiredo JM, Louis ED. Demoralization in Parkinson disease. Neurology 2018, 90: e1613-e1617. PMID: 29618626, PMCID: PMC5931805, DOI: 10.1212/wnl.0000000000005425.Peer-Reviewed Original ResearchConceptsDisease Rating ScaleParkinson's diseasePD cohortPatient Health Questionnaire-9 scoreOutpatient movement disorder clinicYounger ageUnified Parkinson's Disease Rating ScaleParkinson's Disease Rating ScaleMovement Disorders ClinicPart III scoreStepwise logistic regressionOverall cohortMotor dysfunctionDisorders ClinicDiagnostic criteriaTreatment approachesScale scoreLogistic regressionRating ScaleCohortControl participantsMarital statusPsychosomatic researchDepressed individualsDepressionSlower saccadic reading in Parkinson’s disease
Jehangir N, Yu CY, Song J, Shariati MA, Binder S, Beyer J, Santini V, Poston K, Liao YJ. Slower saccadic reading in Parkinson’s disease. PLOS ONE 2018, 13: e0191005. PMID: 29364897, PMCID: PMC5783375, DOI: 10.1371/journal.pone.0191005.Peer-Reviewed Original ResearchConceptsUnified Parkinson's Disease Rating ScaleDuration of diseasePD patientsDisease Rating ScaleParkinson's diseaseQuality of lifeConvergence insufficiencyVisual Functioning Questionnaire-25Parkinson's Disease Rating ScaleDegeneration of dopaminergicVFQ-25 scoresMontreal Cognitive Assessment (MoCA) testAbnormal eye movementsNon-motor deficitsIdiopathic Parkinson's diseaseNational Eye InstituteAge-matched controlsKing-Devick testCognitive Assessment testEye InstituteMoCA scoresPatientsControl groupClinical settingMotor difficulties
2017
Botulinum Toxin in Parkinson Disease Tremor A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach
Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Parkinson Disease Tremor A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. Mayo Clinic Proceedings 2017, 92: 1359-1367. PMID: 28789780, DOI: 10.1016/j.mayocp.2017.06.010.Peer-Reviewed Original ResearchConceptsDisease Rating ScaleHand weaknessPatients' perceptionsUnified Parkinson's Disease Rating ScaleParkinson's Disease Rating ScaleAdministration of onabotulinumtoxinASevere hand weaknessUse of onabotulinumtoxinAPatient Global ImpressionClinical rating scoresTreatment of tremorParkinson's disease tremorIncobotulinumtoxinA injectionsCrossover trialGlobal ImpressionGrip strengthRest tremorBotulinum toxinPD tremorPostural tremorTreatment efficacyClinical practiceSignificant improvementEssential tremorHand strength
2014
Determinants of Objectively Measured Physical Functional Performance in Early to Mid‐stage Parkinson Disease
Kluger BM, Brown RP, Aerts S, Schenkman M. Determinants of Objectively Measured Physical Functional Performance in Early to Mid‐stage Parkinson Disease. PM&R 2014, 6: 992-998. PMID: 24880056, PMCID: PMC4247341, DOI: 10.1016/j.pmrj.2014.05.013.Peer-Reviewed Original ResearchConceptsMid-stage Parkinson's diseaseUnified Parkinson's Disease Rating ScalePhysical functional performanceDisease Rating ScaleParkinson's diseaseNonmotor symptomsFunctional limitationsContinuous Scale Physical Functional Performance TestTertiary academic medical centerCognitive functionParkinson's Disease Rating ScaleCross-sectional baseline dataFunctional performance outcomesMid-stage diseaseProfound functional limitationsRandomized clinical trialsModerate Parkinson's diseaseAcademic medical centerFunctional performance testsOverall cognitive statusFunctional performanceCS-PFPStepwise linear regression modelAdvanced diseaseRegression models
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply